XOMA Corp

NASDAQ:XOMAUnited States

Apr 3, 2024

Show headlines and story abstract

• *DJ News On Kinnate Biopharma Inc. (KNTE) Now Under XOMA, from 5:08PM ET on Wednesday Apr 03, 2024 by Dow Jones

  5:08PM ET on Wednesday Apr 03, 2024 by Dow Jones
  Companies Mentioned: XOMA, KNTE

• XOMA Corporation Announces Closing of Tender Offer, from 9:00AM ET on Wednesday Apr 03, 2024 by GlobeNewswire

  9:00AM ET on Wednesday Apr 03, 2024 by GlobeNewswire
  Companies Mentioned: XOMA, KNTE

• XOMA Corporation Announces Closing of Tender Offer, from 9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones

  9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
  Companies Mentioned: XOMA, KNTE
  
  XOMA Corporation Announces Closing of Tender Offer
  
  Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
  
  EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024.
  

• Press Release: XOMA Corporation Announces Closing of Tender Offer, from 9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones

  9:00AM ET on Wednesday Apr 03, 2024 by Dow Jones
  Companies Mentioned: XOMA
  
  XOMA Corporation Announces Closing of Tender Offer
  
  Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right
  
  EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Kinnate Biopharma Inc. (NASDAQ: KNTE) common stock for a price per share of $2.5879 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Price") representing the right to receive 85% of the net proceeds from any out license or sale of Kinnate programs effected within one year of closing of the merger and 100% of the net proceeds resulting from Kinnate's sale of exarafenib and other pan-RAF program assets to Pierre Fabre Laboratories, as announced on March 1, 2024.